Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLife Science Regulatory News (LABS)

  • This share is currently suspended. It was suspended at a price of 43.10
  • There is currently no data for LABS

Form 8.3

2 Feb 2026 12:10

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

SAMSON ROCK CAPITAL LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

LIFE SCIENCE REIT PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

30/01/2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES - BRITISH LAND COMPANY PLC, THE

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

1p ORDINARY

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

(2) Cash-settled derivatives:

28,550,000

8.16

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

28,550,000

8.16

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

1p ORDINARY

Equity Swap

Increasing a long position

1,400,000

42.65 GBp

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

02/02/2026

Contact name:

Alistair Monro

Telephone number*:

02039941800

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260202801276/en/

Copyright Business Wire 2026

Date   Source Headline
11th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
11th Aug 20251:29 pmGNWForm 8.3 - Life Science REIT Plc
11th Aug 202510:55 amRNSForm 8.3 - LIFE SCIENCE REIT PLC
11th Aug 202510:21 amRNSForm 8.5 (EPT/RI)
8th Aug 20254:09 pmRNSForm 8.3 - Life Science REIT plc
8th Aug 20253:38 pmRNSForm 8.3 - Life Science REIT plc - REPLACEMENT
8th Aug 20253:28 pmRNSForm 8.3 - Life Science REIT plc - REPLACEMENT
8th Aug 20253:27 pmRNSForm 8.3 - Life Science REIT plc
8th Aug 20252:48 pmRNSForm 8.3 - Life Science REIT plc
8th Aug 20251:26 pmGNWForm 8.3 - Life Science REIT Plc
8th Aug 202511:29 amRNSForm 8.5 (EPT/RI)
8th Aug 202510:10 amRNSForm 8.3 - Life Science REIT plc
7th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
6th Aug 20253:26 pmBUSForm 8.3 - Life Science REIT plc
6th Aug 202512:52 pmGNWForm 8.3 - Life Science REIT Plc
6th Aug 202511:51 amRNSForm 8.3 - Life Science REIT plc
6th Aug 202510:42 amRNSForm 8.3 - Life Science Reit Plc
6th Aug 202510:16 amRNSForm 8.5 (EPT/RI)
5th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
5th Aug 20252:20 pmRNSForm 8.3 - Life Science REIT plc
5th Aug 20252:10 pmGNWForm 8.3 - Life Science REIT Plc
5th Aug 202510:35 amRNSForm 8.5 (EPT/RI)
4th Aug 20254:54 pmRNSForm 8.3 - Life Science REIT plc
4th Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
4th Aug 20252:11 pmGNWForm 8.3 - Life Science REIT Plc
4th Aug 20251:36 pmRNSForm 8.3 - Life Science REIT plc
4th Aug 202511:21 amRNSForm 8.3 - Life Science REIT plc
4th Aug 202510:51 amRNSForm 8.3 - LIFE SCIENCE REIT PLC
1st Aug 20253:20 pmRNSForm 8.3 - Life Science REIT plc
1st Aug 20252:30 pmRNSForm 8.3 - Life Science REIT plc
1st Aug 202511:12 amRNSForm 8.3 - LIFE SCIENCE REIT PLC
1st Aug 202510:54 amRNSForm 8.5 (EPT/RI)
31st Jul 20253:46 pmRNSForm 8.3 - Life Science
31st Jul 20253:20 pmRNSForm 8.3 - Life Science REIT plc
31st Jul 20251:22 pmGNWForm 8.3 - Life Science REIT Plc
31st Jul 202510:38 amRNSForm 8.5 (EPT/RI)
30th Jul 20253:48 pmRNSHolding(s) in Company
30th Jul 20253:26 pmBUSForm 8.3 - Life Science REIT plc
30th Jul 20253:20 pmRNSForm 8.3 - Life Science REIT plc
30th Jul 20252:56 pmGNWForm 8.3 - Life Science REIT Plc
30th Jul 202512:35 pmRNSForm 8.3 - Life Science REIT plc
30th Jul 202510:40 amRNSForm 8.5 (EPT/RI)
29th Jul 20254:37 pmRNSForm 8.3 - Life Science
29th Jul 20253:26 pmBUSForm 8.3 - Life Science REIT plc
29th Jul 20253:20 pmRNSForm 8.3 - Life Science REIT plc
29th Jul 20253:02 pmGNWForm 8.3 - Life Science REIT Plc
29th Jul 20252:29 pmRNSForm 8.3 - Life Science REIT plc
29th Jul 202510:36 amRNSForm 8.3 - Life Science REIT PLC
29th Jul 20259:40 amRNSForm 8.5 (EPT/RI)
28th Jul 20254:47 pmRNSForm 8.3 - Life Science

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.